On Friday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) opened higher 8.31% from the last session, before settling in for the closing price of $3.85. Price fluctuations for RXRX have ranged from $3.79 to $12.36 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -35.28%. Company’s average yearly earnings per share was noted 7.54% at the time writing. With a float of $414.89 million, this company’s outstanding shares have now reached $485.21 million.
Recursion Pharmaceuticals Inc (RXRX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Recursion Pharmaceuticals Inc is 20.41%, while institutional ownership is 48.86%. The most recent insider transaction that took place on Nov 19 ’25, was worth 166,400. In this transaction Chief Executive Officer of this company sold 40,000 shares at a rate of $4.16, taking the stock ownership to the 913,839 shares. Before that another transaction happened on Nov 19 ’25, when Company’s Officer proposed sale 40,000 for $4.16, making the entire transaction worth $166,400.
Recursion Pharmaceuticals Inc (RXRX) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.53 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.42) by -0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.13% during the next five years compared to -35.28% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Check out the current performance indicators for Recursion Pharmaceuticals Inc (RXRX). In the past quarter, the stock posted a quick ratio of 4.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 49.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.81, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.23 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Looking closely at Recursion Pharmaceuticals Inc (NASDAQ: RXRX), its last 5-days average volume was 30.17 million, which is a jump from its year-to-date volume of 29.82 million. As of the previous 9 days, the stock’s Stochastic %D was 15.61%.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 10.68%, which indicates a significant decrease from 23.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.35 in the past 14 days, which was lower than the 0.39 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.19, while its 200-day Moving Average is $5.53. However, in the short run, Recursion Pharmaceuticals Inc’s stock first resistance to watch stands at $4.34. Second resistance stands at $4.50. The third major resistance level sits at $4.75. If the price goes on to break the first support level at $3.93, it is likely to go to the next support level at $3.68. Now, if the price goes above the second support level, the third support stands at $3.52.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
There are currently 520,643K shares outstanding in the company with a market cap of 2.17 billion. Presently, the company’s annual sales total 58,840 K according to its annual income of -463,660 K. Last quarter, the company’s sales amounted to 5,180 K and its income totaled -162,250 K.
